TABLE 6.
Prognostic value of markers when stratifying for diffuse large B‐cell lymphoma (DLBCL) subtypes
| Marker | P value (Kaplan–Meier with log‐rank test) | |||||
|---|---|---|---|---|---|---|
| OS | PFS | |||||
| DLBCL NOS | EBER+DLBCL | HGBCL | DLBCL NOS | EBER+DLBCL | HGBCL | |
| CD68 | 0.011 | 0.538 | NA | 0.001 | 0.705 | NA |
| CD16 | 0.142 | 0.673 | 0.317 | 0.033 | 0.736 | 0.317 |
| MITF | 0.007 | 0.283 | 0.317 | 0.136 | 0.050 | 0.317 |
| CD163 | 0.001 | 0.314 | 0.515 | 0.002 | 0.610 | 0.918 |
| PTX3 | 0.007 | 0.003 | NA | 0.012 | NA | NA |
| IL‐10 | <0.001 | NA | NA | <0.001 | NA | NA |
| FOXP3 | 0.002 | 0.110 | NA | 0.061 | 0.920 | NA |
| RGS1 | 0.140 | 0.275 | 0.157 | 0.658 | 0.307 | 0.157 |
Abbreviations: EBER, Epstein–Barr virus‐encoded small RNA; HGBCL, high‐grade B‐cell lymphoma; IL‐10, interleukin‐10; MITF, microphthalmia transcription factor; NA, nonassessable; NOS, not otherwise specified; OS, overall survival; PFS, progression‐free survival; PTX3, pentraxin 3; RGS1, regulator of G‐protein signaling 1.